Search
for
Sort by
Research 331–360 of 523
- Kyoh® Rocket Leaf Extract Regulates Proliferation and VEGF and FGF7 Expression in Human Dermal Follicle Papilla Cells
- Hydrogel forming microneedles loaded with VEGF and Ritlecitinib/polyhydroxyalkanoates nanoparticles for mini-invasive androgenetic alopecia treatment
- Dermatologists’ Perspectives and Real-World Assessment of Alopecia Areata Severity, Burden, and Healthcare Resource Utilization in Adults in the United Arab Emirates
- Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities
- Identification of SLC40A1, LCN2, CREB5, and SLC7A11 as ferroptosis-related biomarkers in alopecia areata through machine learning
- Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases
- Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
- Alopecia areata
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
- Advances in the mechanism and new therapies of alopecia areata
- High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Baricitinib in the Treatment of Frontal Fibrosing Alopecia: Mid Trial Update
- Patient Validation of Estimation of Health Utility Values in Alopecia Areata
- Effect of tofacitinib on the expression of noggin/BMP-4 and hair growth stimulation in mice
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- Treatment of frontal fibrosing alopecia: literature review 2020-2025
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
- <i>IKZF1</i> and Ikaros Overexpression Results in Alopecia Areata‐Like Phenotype in Mice
- 056 IKZF1 and IKAROS overexpression contributes to the pathogenesis of alopecia areata
- Oral tofacitinib for recalcitrant lichen planus pigmentosus: A hospital-based retrospective study
- Therapeutic update on alopecia areata: a critical review of standard and emerging targeted therapies
- Baricitinib: Exploring the Safety Profile for the Treatment of Alopecia Areata
- Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study
- The Frontal Fibrosing Alopecia Treatment Dilemma
- The first 20 years of skin of color dermatology: An era of advancements in skin, hair, and nail disorders
- Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A Systematic Review and Meta-Analysis of Controlled Trials
- Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3